Login / Signup

Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design.

Munyaradzi DimairoElizabeth CoatesPhilip PallmannSusan ToddSteven A JuliousThomas JakiJames WasonAdrian P ManderChristopher J WeirFranz KoenigMarc K WaltonKatie BiggsJon NichollToshimitsu HamasakiMichael A ProschanJohn A ScottYuki AndoDaniel HindDouglas G Altman
Published in: BMC medicine (2018)
We hope that making the development processes, methods, and all supporting information that aided decision-making transparent will enhance the acceptability and quick uptake of the guideline. This will also help other groups when developing similar CONSORT extensions. The guideline is applicable to all randomised trials with an AD and contains minimum reporting requirements.
Keyphrases
  • clinical trial
  • open label
  • decision making
  • double blind
  • study protocol
  • placebo controlled
  • randomized controlled trial
  • healthcare
  • emergency department
  • clinical practice
  • adverse drug